Sugi Predict

Sugi Predict / Compounds / SCHEMBL538592

SCHEMBL538592

SCHEMBL538592

Fc1cc(Br)ccc1-c1ccccc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 3/20 0.46
▸ MAPK1 P28482 2/20 0.46
▸ PTGS1 P23219 3/20 0.46
▸ LMNA P02545 3/20 0.46
▸ MEN1 O00255 2/20 0.46
▸ PTGS2 P35354 2/20 0.46
▸ KMT2A Q03164 2/20 0.46
▸ HPGD P15428 2/20 0.46
▸ FABP2 P12104 1/20 0.46
▸ TSHR P16473 1/20 0.46
▸ AKR1C4 P17516 1/20 0.46
▸ ADRA2B P18089 1/20 0.46
▸ CHRM3 P20309 1/20 0.46
▸ HTR2C P28335 1/20 0.46
▸ DRD3 P35462 1/20 0.46
▸ AKR1C3 P42330 1/20 0.46
▸ AKR1C2 P52895 1/20 0.46
▸ AKR1C1 Q04828 1/20 0.46
▸ SLC22A6 Q4U2R8 1/20 0.46
▸ CYP1A2 P05177 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10799367 0.98 PTGS1 (0.45) ALDH1A1MAPK1PTGS1LMNAMEN1
SCHEMBL2010580 0.89 MMP1 (0.47) ALDH1A1PTGS1LMNAMEN1PTGS2
SCHEMBL8216773 0.84 ALOX5AP (0.41) ALDH1A1MAPK1MEN1KMT2ACYP1A2
SCHEMBL28462601 0.83 MAPK1 (0.46) ALDH1A1MAPK1LMNAMEN1KMT2A
SCHEMBL10269866 0.83 ALOX5AP (0.49) ALDH1A1PTGS1LMNAMEN1PTGS2
SCHEMBL10269901 0.82 ALOX5AP (0.45) HPGDMAPTALOX5APFEN1NMUR2
SCHEMBL31010675 0.81 L3MBTL1 (0.41) ALDH1A1MAPK1MEN1KMT2AHPGD
SCHEMBL14520998 0.81 DGAT1 (0.46) ALDH1A1LMNAHPGDALOX5APFEN1
SCHEMBL31310573 0.81 DGAT1 (0.46) ALDH1A1LMNAHPGDALOX5APFEN1
SCHEMBL11728016 0.80 PTPRC (0.47) ALDH1A1MAPK1LMNAMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 414 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-120040283-A Flurbiprofen axetil salt and preparation method and application thereof 广东莱恩医药研究院有限公司 2025-05-27 — — CN claimed
CN-119661356-A Preparation method of flurbiprofen axetil 浙江东亚药业股份有限公司 2025-03-21 — — CN claimed
CN-119361834-A Electrolyte and battery and electricity utilization device containing same 浙江大学 2025-01-24 — — CN claimed
CN-116124907-B Method for detecting impurities in 4-bromo-2-fluorobiphenyl 远大生命科学(辽宁)有限公司 2024-11-26 — — CN claimed
CN-116102397-B Flurbiprofen Process for the preparation of a compound containing a compound selected from the group consisting of 沈阳药科大学 2024-08-30 — — CN claimed
CN-118515555-A Preparation method of S-flurbiprofen 威智医药股份有限公司 2024-08-20 — — CN claimed
CN-114544785-B Flurbiprofen and detection method of impurities thereof 远大生命科学(鞍山)有限公司 2024-06-21 — — CN claimed
CN-117645535-A Flurbiprofen intermediate and preparation method of flurbiprofen 河北鼎泰制药有限公司 2024-03-05 — — CN claimed
CN-116715689-A Synthesis method of flurbiprofen and intermediate thereof 珠海市海瑞德生物科技有限公司 2023-09-08 — — CN claimed
CN-116124907-A Method for detecting impurities in 4-bromo-2-fluorobiphenyl 远大生命科学(辽宁)有限公司 2023-05-16 — — CN claimed
CN-102030651-A Synthesis method of 2-fluo-4-bromobiphenyl ethyl formate LIANGYANG SHENGHUA S & T CO LTD 2011-04-27 — — CN claimed
US-20100125139-A1 PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF BANKSTON DONALD 2010-05-20 — — US claimed
EP-1370553-B1 RHO-KINASE INHIBITORS BAYER AG (US) 2006-05-10 — — EP claimed
EP-1542992-A2 PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF Bayer Corporation (US) 2005-06-22 — — EP claimed
WO-2004029045-A2 PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF BAYER PHARMACEUTICALS CORPORATION (US) 2004-04-08 — — WO claimed
EP-1370553-A2 RHO-KINASE INHIBITORS Bayer Corporation (US) 2003-12-17 — — EP claimed
US-20030220357-A1 Process for preparing quinazoline Rho-kinase inhibitiors and intermediates thereof BAYER HEALTHCARE LLC 2003-11-27 — — US claimed
WO-2002076976-A2 RHO-KINASE INHIBITORS BAYER CORPORATION (US) 2002-10-03 — — WO claimed
US-5536870-A Process for preparing olefins ALBEMARLE CORPORATION (US) 1996-07-16 — — US claimed
US-5254776-A Synthesis of bromobiphenyls MALLINCKRODT SPECIALTY CHEMICALS COMPANY (US) 1993-10-19 — — US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030220357-A1 Process for preparing quinazoline Rho-kinase inhibitiors and intermediates thereof ROCK1, ROCK2, RHOT2 ALDH1A1 3717/4885MAPK1 185/4885PTGS1 308/4885
US-20100125139-A1 PROCESS FOR PREPARING QUINAZOLINE RHO-KINASE INHIBITORS AND INTERMEDIATES THEREOF ROCK1, ROCK2, CIT ALDH1A1 4305/4885MAPK1 203/4885PTGS1 341/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.